Immunology Archives - Abzena


MHC Associated Peptide Proteomics

Case Study MAPPs for Vaccine Design To identify MHC class I presented antigens derived from influenza strain H1N1, two[...]


EpiScreen™ Epitope Mapping Fact Sheet

Further information on Abzena’s accurate and sensitive ex vivo T cell epitope identification technology including[...]


iTope™ and TCED™ Fact Sheet

More information on Abzena’s iTope™ and TCED™ technology including a detailed look at the results.


EpiScreen™ Time Course T Cell Assay Fact Sheet

More information on the EpiScreen™ time course T cell assay and a case study showing the potential immunogenicity[...]



Abzena’s Biopharmaceutical Discovery & Development Symposium

26 April 2018

Abzena are hosting the first Biopharmaceutical Discovery & Development Symposium to showcase the latest technologies[...] Read more


A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors.

Carl I. Webster, Christine J. Bryson, Edward A. Cloake, Tim D. Jones, Mark J. Austin, Anette C. Karle, Sebastian[...] Read more

Small Amounts of Sub-Visible Aggregates Enhance the Immunogenic Potential of Monoclonal Antibody Therapeutics

Maryam Ahmadi, Christine J. Bryson, Edward A. Cloake, Katie Welch, Vasco Filipe, Stefan Romeijn, Andrea Hawe, Wim[...] Read more

Drug Discovery Tutorial: Detection and Reduction of Immunogenicity

Drug Discovery Tutorial: Detection and Reduction of Immunogenicity This article discusses how early removal of T-cell[...] Read more

Assessing Immunogenicity Using Ex Vivo T cell Assays

Assessing Immunogenicity Using Ex Vivo T cell Assays This article discusses Antitope’s developed highly sensitive ex[...] Read more

Pre-clinical considerations in the assessment of immunogenicity for protein therapeutics

Baker M, Carr F. Curr Drug Saf. 2010 Oct;5(4):308-13. Abstract Protein therapeutics offer distinct advantages over other[...] Read more

Immunogenicity of protein therapeutics The key causes, consequences and challenges

Matthew P. Baker,* Helen M. Reynolds, Brooke Lumicisi and Christine J. Bryson, Self/Nonself, Volume 1, Issue 4, 2010[...] Read more

Prediction of immunogenicity of therapeutic proteins: validity of computational tools.

BioDrugs. 2010 Feb 1;24(1):1-8. doi: 10.2165/11318560-000000000-00000. Bryson CJ, Jones TD, Baker MP. Abstract Most[...] Read more

In vitro screening for antibody immunogenicity

In book: recombinant antibodies for immunotherapy, Chapter: In vitro screening for antibody immunogenicity, Publisher:[...] Read more

New approaches to prediction of immune responses to therapeutic proteins during preclinical development.

Drugs R D. 2008;9(6):385-96. doi: 10.2165/0126839-200809060-00004, Perry LC, Jones TD, Baker MP. Abstract Clinical[...] Read more

Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays

J Pharm Biomed Anal. 2007 Mar 12;43(4):1256-61. Epub 2006 Nov 21. Jaber A, Baker M. Abstract Recombinant homologues of[...] Read more


Abzena plc and UCL Medical Research Council grant awarded to collaboration group developing novel autoimmune therapy

Cambridge and London, UK, 1 March 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences[...] Read more

Abzena and Baylor Scott & White Research Institute team up to form Denceptor Therapeutics to develop novel immunotherapies

Cambridge, UK and Dallas, US  – July 2016 – Abzena plc (AIM: ABZA, “Abzena” or the “Group”) and the Baylor[...] Read more

We’re changing the way we brand our businesses

To provide our Partners with a single identity for the services and technologies offered across Antitope, PacificGMP,[...] Read more

Appointment of Campbell Bunce as Senior Vice President, Scientific Operations

Adds further immunology expertise to Executive Management Team Cambridge, UK – Abzena plc (AIM:ABZA, ‘Abzena’), a[...] Read more

Abzena to provide Apitope with Analytical Support for Development of a Novel Treatment for Factor VIII Inhibitors in Haemophilia A Patients

Cambridge, UK and Diepenbeek, Belgium – Abzena plc (AIM:ABZA), a life sciences company providing services and[...] Read more

Antitope, INSERM and Baylor Institute for Immunology Research to collaborate to produce manufacturing cell lines for two novel vaccines for HIV

Cambridge, UK – Antitope Limited (“Antitope”), an Abzena company (AIM: ABZA) that provides services and[...] Read more

Antitope and Synthon Announce Collaboration

Cambridge, UK and Nijmegen, the Netherlands, 2 July 2014 – Antitope Limited (“Antitope”), an Abzena company, today[...] Read more

Antitope and Baylor Institute for Immunology Research to Collaborate to Produce Manufacturing Cell Line for Novel Therapeutic Dendritic-cell-targeting Vaccine

London, UK and Dallas, TX, USA, 6 June 2014 – Antitope Limited (“Antitope”), an Abzena company, today announced[...] Read more

Antitope and Rottapharm Madaus Complete Successful Immunogenicity Assessment Research Collaboration

Cambridge UK, 31 January 2013 – Antitope Ltd., UK (“Antitope”) today announced the completion of a[...] Read more

Antitope Announces Research Collaboration with Ablynx

Cambridge, UK. 25 August 2010 – Antitope Ltd. (“Antitope”) today announced a research collaboration with Ablynx[...] Read more

Interested in our services? Get In Touch